United Therapeutics Corporation (UTHR) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum September 23, 2026 1:20 PM EDT
Company Participants
Martine Rothblatt – Founder, Chairman & CEO
James Edgemond – CFO & Treasurer
Conference Call Participants
Jeffrey Walch – Bernstein Institutional Services LLC, Research Division
Presentation
Jeffrey Walch
Bernstein Institutional Services LLC, Research Division
Thank you so much for joining us today. We’re really excited here from our Healthcare Leaders and Disruptors Conference. It’s excellent to have such a great community be here to hear from what I would say are healthcare leaders and disruptors, and we’re here to talk to our next set from United Therapeutics. I have the pleasure to introduce Dr. Martine Rothblatt, Founder and Chief Executive Officer, as well as James Edgemond, Chief Financial Officer. Before we get into Q&A, we’re going to spend a couple of minutes where both of them have some prepared remarks. So, I’ll turn it over to them.
Martine Rothblatt
Founder, Chairman & CEO
Thanks so much, Jeffrey. Super happy to be here at the Bernstein Conference. United Therapeutics is poised right now for an exponential growth trajectory, unlike anything that we’ve yet experienced and really unlike much that you can ever see in the biotechnology industry. We’re right now in the middle of launching 14 significant products that will completely transform the revenue and profit profile of our company.
Those 14 products are a nebulized form of Tyvaso for IPF and PPF. These are 2 different lung fibrotic diseases. The NDA for Tyvaso for IPF has already been accepted for filing by the FDA with a PDUFA date coming up early next year. And this drug in its Phase III trials demonstrated the greatest improvement in patient outcome of any drug that had ever been tried or developed in pulmonary